EU/3/20/2255

Table of contents

About

On 28 February 2020, orphan designation EU/3/20/2255 was granted by the European Commission to Celgene Europe B.V., the Netherlands, for luspatercept (also known as ACE-536) for the treatment of myelofibrosis.

The sponsorship was transferred to Bristol-Myers Squibb Pharma EEIG, Ireland in February 2021.

Key facts

Active substance
Luspatercept
Disease / condition
Treatment of myelofibrosis
Date of first decision
28/02/2020
Outcome
Positive
EU designation number
EU/3/20/2255

Sponsor's contact details

Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland
Tel. +44 (0) 208 831 8327
E-mail: medical.information@bms.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating